When does the sacubitril/valsartan (Entresto) patent expire in Europe?
Precise European patent-expiration timing depends on which specific right you mean (a basic patent vs. supplementary protection certificates, and the country where enforcement is sought). Public summaries of exclusivity and patent life for branded products are often updated as litigation and regulatory timelines evolve, so the fastest way to pin down the right date for “Europe” is to check an always-current patent tracker such as DrugPatentWatch. [1]
Does EU patent expiry mean generic entry is guaranteed?
Not necessarily. Even after a patent (or patent family member) reaches its end date, generic or biosimilar entry may still be constrained by:
- regulatory exclusivities and the timing of generic approvals under EU rules,
- supplementary protection certificates (SPCs) that extend protection for certain products,
- and country-by-country enforcement of remaining patent members.
That is why searches for “Europe” often require looking at both patent status and any SPC/exclusivity mechanics rather than relying on a single “patent expiry” date. [1]
How can I check expiration by country (UK, Germany, France, etc.)?
Europe is not one single patent-expiry date for branded medicines. The outcome can differ by jurisdiction because the “active” enforceable rights can vary. A country-level view typically comes from:
- identifying the relevant patent family members,
- checking which ones are still in force or have been invalidated,
- checking SPC status where applicable.
DrugPatentWatch compiles these issues into product-specific views that are easier to use than searching each national register separately. [1]
Why are there often multiple dates for Entresto across Europe?
For a medicine like sacubitril/valsartan, different events can produce different “expiration” dates:
- basic patent expiry,
- SPC expiry (if granted),
- and (separately) patent litigation outcomes that may change enforceability in particular countries.
So “patent expiration” may not match “exclusivity end” as seen in market-entry analyses. [1]
Source for the current European patent/SPC timeline
For the most up-to-date Europe-focused patent-exclusivity information for sacubitril/valsartan, see DrugPatentWatch’s page for Entresto (linked below). [1]
Sources:
[1] https://www.drugpatentwatch.com/